Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ARMP NASDAQ:CALT NASDAQ:JBIO NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$8.26+1.8%$10.18$1.74▼$16.34$296.98M1.3157,002 shs20,679 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AJBIOJade Biosciences$23.08-1.1%$19.38$6.57▼$28.00$1.14B1.52457,397 shs108,091 shsOLMAOlema Pharmaceuticals$13.92-0.3%$14.98$3.89▼$36.26$1.21B2.051.41 million shs212,112 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals-4.02%-7.94%-35.04%-3.22%+260.89%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%JBIOJade Biosciences+6.67%-6.90%-0.68%+60.41%+2,333,999,900.00%OLMAOlema Pharmaceuticals+6.56%+2.80%-15.80%-41.37%+174.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$8.26+1.8%$10.18$1.74▼$16.34$296.98M1.3157,002 shs20,679 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AJBIOJade Biosciences$23.08-1.1%$19.38$6.57▼$28.00$1.14B1.52457,397 shs108,091 shsOLMAOlema Pharmaceuticals$13.92-0.3%$14.98$3.89▼$36.26$1.21B2.051.41 million shs212,112 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals-4.02%-7.94%-35.04%-3.22%+260.89%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%JBIOJade Biosciences+6.67%-6.90%-0.68%+60.41%+2,333,999,900.00%OLMAOlema Pharmaceuticals+6.56%+2.80%-15.80%-41.37%+174.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARMPArmata Pharmaceuticals 2.67Moderate Buy$15.0081.53% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AJBIOJade Biosciences 2.89Moderate Buy$34.3348.79% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10216.79% UpsideCurrent Analyst Ratings BreakdownLatest ARMP, OLMA, JBIO, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026ARMPArmata Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/13/2026OLMAOlema Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.005/11/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/11/2026JBIOJade Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $32.005/11/2026JBIOJade Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $34.004/27/2026JBIOJade Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $45.004/24/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026JBIOJade Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/27/2026OLMAOlema Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARMPArmata Pharmaceuticals$4.90M61.91N/AN/A($8.49) per share-0.97CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74JBIOJade BiosciencesN/AN/AN/AN/A$6.01 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARMPArmata Pharmaceuticals-$173.80M-$1.64N/AN/AN/A-5,432.79%N/A-75.29%N/ACALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AJBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/AOLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%N/ALatest ARMP, OLMA, JBIO, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ARMPArmata Pharmaceuticals-$0.38-$3.16-$2.78-$3.16$0.74 million$0.79 million5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A3/25/2026Q4 2025ARMPArmata Pharmaceuticals-$0.19-$3.42-$3.23-$3.42$0.74 million$1.09 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/A3/6/2026Q4 2025JBIOJade Biosciences-$0.45-$0.11+$0.34-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARMPArmata PharmaceuticalsN/A0.640.64CALTCalliditas Therapeutics AB (publ)9.442.692.59JBIOJade BiosciencesN/A14.2914.29OLMAOlema Pharmaceuticals0.0110.8810.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARMPArmata Pharmaceuticals3.57%CALTCalliditas Therapeutics AB (publ)2.83%JBIOJade BiosciencesN/AOLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipARMPArmata Pharmaceuticals84.50%CALTCalliditas Therapeutics AB (publ)2.20%JBIOJade Biosciences23.06%OLMAOlema Pharmaceuticals12.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARMPArmata Pharmaceuticals7036.71 million5.69 millionNot OptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionNo DataJBIOJade Biosciences2049.36 million37.98 millionN/AOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableARMP, OLMA, JBIO, and CALT HeadlinesRecent News About These CompaniesLifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)May 19 at 12:08 AM | theglobeandmail.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 19 at 4:30 PM | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 17, 2026 | americanbankingnews.comOlema: The Market Overreacted To Roche's SERD FailureMay 15, 2026 | seekingalpha.comOlema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $35.00 by Analysts at GuggenheimMay 14, 2026 | americanbankingnews.comOlema Oncology Reports First Quarter 2026 Financial and Operating ResultsMay 12, 2026 | markets.businessinsider.comOlema Pharmaceuticals inc Ordinary Shares OLMAMay 10, 2026 | morningstar.comMAssessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The BoardMay 10, 2026 | finance.yahoo.comOlema Pharmaceuticals (OLMA) to Release Quarterly Earnings on TuesdayMay 10, 2026 | americanbankingnews.comPier Capital LLC Decreases Position in Olema Pharmaceuticals, Inc. $OLMAMay 8, 2026 | marketbeat.comOlema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comJennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMAMay 2, 2026 | marketbeat.comPictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMAMay 2, 2026 | marketbeat.comOlema Pharmaceuticals Adds Veteran Director to Support GrowthApril 29, 2026 | tipranks.comOlema Oncology Appoints Prakash Raman, Ph.D., to Board of DirectorsApril 29, 2026 | globenewswire.comWall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell"April 27, 2026 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 22, 2026 | marketbeat.comOlema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comOlema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingApril 18, 2026 | theglobeandmail.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARMP, OLMA, JBIO, and CALT Company DescriptionsArmata Pharmaceuticals NYSEAMERICAN:ARMP$8.26 +0.14 (+1.76%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 05/19/2026Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Jade Biosciences NASDAQ:JBIO$23.08 -0.27 (-1.14%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$13.92 -0.04 (-0.28%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Corpay’s Quiet Strength Is Winning Wall Street Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
